These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16778322)

  • 1. Animal models for vaccine studies for visceral leishmaniasis.
    Garg R; Dube A
    Indian J Med Res; 2006 Mar; 123(3):439-54. PubMed ID: 16778322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental models for leishmaniasis and for testing anti-leishmanial vaccines.
    Hommel M; Jaffe CL; Travi B; Milon G
    Ann Trop Med Parasitol; 1995 Dec; 89 Suppl 1():55-73. PubMed ID: 8745928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interpretation of laboratory data during cryptic leishmaniasis in dog].
    Gravino AE
    Parassitologia; 2004 Jun; 46(1-2):227-9. PubMed ID: 15305723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visceral leishmaniasis: experimental models for drug discovery.
    Gupta S;
    Indian J Med Res; 2011 Jan; 133(1):27-39. PubMed ID: 21321417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Animal models for the study of leishmaniasis immunology.
    Loría-Cervera EN; Andrade-Narváez FJ
    Rev Inst Med Trop Sao Paulo; 2014; 56(1):1-11. PubMed ID: 24553602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syrian Hamster as an Advanced Experimental Model for Visceral Leishmaniasis.
    Jiménez-Antón MD; Grau M; Olías-Molero AI; Alunda JM
    Methods Mol Biol; 2019; 1971():303-314. PubMed ID: 30980312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canine Leishmania vaccines: still a long way to go.
    Gradoni L
    Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine.
    Gradoni L
    Vet Parasitol; 2001 Sep; 100(1-2):87-103. PubMed ID: 11522409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines in leishmaniasis: advances in the last five years.
    Brodskyn C; de Oliveira CI; Barral A; Barral-Netto M
    Expert Rev Vaccines; 2003 Oct; 2(5):705-17. PubMed ID: 14711330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
    Lemesre JL; Holzmuller P; Cavaleyra M; Gonçalves RB; Hottin G; Papierok G
    Vaccine; 2005 Apr; 23(22):2825-40. PubMed ID: 15780731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.
    Schaut RG; Grinnage-Pulley TL; Esch KJ; Toepp AJ; Duthie MS; Howard RF; Reed SG; Petersen CA
    Vaccine; 2016 Oct; 34(44):5225-5234. PubMed ID: 27665354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
    Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
    Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiparasitic chemotherapy: tinkering with the purine salvage pathway.
    Datta AK; Datta R; Sen B
    Adv Exp Med Biol; 2008; 625():116-32. PubMed ID: 18365663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.
    Osman M; Mistry A; Keding A; Gabe R; Cook E; Forrester S; Wiggins R; Di Marco S; Colloca S; Siani L; Cortese R; Smith DF; Aebischer T; Kaye PM; Lacey CJ
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005527. PubMed ID: 28498840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis.
    Selvapandiyan A; Dey R; Gannavaram S; Solanki S; Salotra P; Nakhasi HL
    Vaccine; 2014 Jun; 32(31):3895-901. PubMed ID: 24837513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCR identification of Leishmania in diagnosis and control of canine Leishmaniasis.
    Gomes AH; Ferreira IM; Lima ML; Cunha EA; Garcia AS; Araújo MF; Pereira-Chioccola VL
    Vet Parasitol; 2007 Mar; 144(3-4):234-41. PubMed ID: 17196339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigenicity of
    Fernández L; Carrillo E; Sánchez-Sampedro L; Sánchez C; Ibarra-Meneses AV; Jimenez MA; Almeida VDA; Esteban M; Moreno J
    Front Immunol; 2018; 9():843. PubMed ID: 29740446
    [No Abstract]   [Full Text] [Related]  

  • 20. Leishmania vaccine development: exploiting the host-vector-parasite interface.
    Reed SG; Coler RN; Mondal D; Kamhawi S; Valenzuela JG
    Expert Rev Vaccines; 2016; 15(1):81-90. PubMed ID: 26595093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.